TG Therapeutics Presents New BRIUMVI Data at AAN 2026, Highlighting Real-World Efficacy
Event summary
- TG Therapeutics presented new data on BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis (RMS) at the AAN 2026 annual meeting.
- Two poster presentations highlighted real-world clinical experience from the ENABLE study and safety/tolerability updates from the ENHANCE study.
- BRIUMVI is a glycoengineered anti-CD20 monoclonal antibody approved for RMS in the U.S. and several other countries.
- The presentations were led by key neurologists from Cleveland Clinic and Missouri Baptist Medical Center.
The big picture
TG Therapeutics' presentation of new BRIUMVI data at AAN 2026 underscores the growing emphasis on real-world evidence in the multiple sclerosis treatment landscape. The company is positioning BRIUMVI as a differentiated therapy in a crowded market, leveraging its unique glycoengineering technology to target CD20-expressing B-cells. The strategic focus on optimizing dosing and demonstrating long-term safety could enhance BRIUMVI's competitive edge, particularly as TG Therapeutics seeks to expand its commercial footprint in a sector dominated by established players like Biogen and Novartis.
What we're watching
- Clinical Validation
- Whether the real-world data from ENABLE will further differentiate BRIUMVI in the competitive RMS market.
- Regulatory Dynamics
- How the safety and tolerability updates from ENHANCE may impact future dosing recommendations and approvals.
- Market Positioning
- The pace at which TG Therapeutics can expand BRIUMVI's commercial reach in both the U.S. and international markets.
Related topics